Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report DOI Creative Commons

Haoyue Qin,

Huan Yan, Xing Zhang

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Дек. 11, 2024

Background The second-line treatment of neuroendocrine tumors (NETs) unknown primary origin remains uncertain. This report presented a patient who received octreotide plus IBI-318 anlotinib as for multiple metastatic NETs lesions after the failure everolimus. Case presentation A 32-year-old male with elevated CEA (197.83 ng/ml) without specific symptoms. contrast-enhanced computed tomography (CT) scan showed lymph nodes and low-density nodules in liver undetermined nature. right supraclavicular node biopsy indicated NET, but tumor remained unknown. PD-L1 expression was negative tissue according to immunohistochemistry. Immunofluorescence CD4 + T cells, CD8 Treg cells were gathered around blood vessels, only few infiltrating lymphocytes tissue. Treatment (30 mg/28 d) everolimus (5 mg qd) led disease progression three cycles. changed IBI318 (400 (10 mg/1-14 d/q3w), leading partial remission, which sustained up last follow-up (June 20, 2023), PFS 11 months. experienced no treatment-related adverse reactions. Conclusions Octreotide achieved benefits advanced first-line failure, even though low expression. case suggests that combining SSAs, TKIs PD-1/PD-L1 inhibitors could be an alternative patients advanced, well-differentiated NETs.

Язык: Английский

Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance DOI Creative Commons
Tommaso Scolaro, Marta Manco, Mathieu Pecqueux

и другие.

Nature Cancer, Год журнала: 2024, Номер 5(8), С. 1206 - 1226

Опубликована: Июнь 6, 2024

Many individuals with cancer are resistant to immunotherapies. Here, we identify the gene encoding pyrimidine salvage pathway enzyme cytidine deaminase (CDA) among top upregulated metabolic genes in several immunotherapy-resistant tumors. We show that CDA cells contributes uridine diphosphate (UDP) pool. Extracellular UDP hijacks immunosuppressive tumor-associated macrophages (TAMs) through its receptor P2Y

Язык: Английский

Процитировано

21
Clinical applications of human organoids DOI
Monique M.A. Verstegen, Robert P. Coppes, Anne Béghin

и другие.

Nature Medicine, Год журнала: 2025, Номер unknown

Опубликована: Фев. 3, 2025

Язык: Английский

Процитировано

9
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling DOI Creative Commons
Mingyao Huang, Xiaoqin Yu, Qing Wang

и другие.

Cell Communication and Signaling, Год журнала: 2024, Номер 22(1)

Опубликована: Янв. 12, 2024

Abstract Objective The CD155/TIGIT axis has attracted considerable interest as an emerging immune checkpoint with potential applications in cancer immunotherapy. Our research focused on investigating the role of checkpoints progression triple-negative breast (TNBC). Methods We evaluated CD155 and TIGIT expression TNBC tissues using both immunohistochemistry (IHC) gene profiling. experiments, vivo vitro, provided evidence that inhibiting pathway reinstates ability CD8 + T cells to generate cytokines. To assess impact signaling blockade, we utilized Glucose Assay Kits Lactate measure alterations glucose lactate levels within cells. employed western blotting (WB) investigate glycolytic-related proteins PI3K/AKT/mTOR pathways following inhibition signaling. Results exhibits heightened a negative correlation extent infiltrating Furthermore, patients demonstrate elevated expression. findings indicate interaction between disrupts metabolism by suppressing activation pathway, ultimately leading reduced production cytokines Both vitro experiments have conclusively demonstrated capacity Moreover, administration blocking antibody against not only inhibits tumor growth but also augments functionality lymphocytes. Conclusions strongly suggest represents promising therapeutic target for treating TNBC.

Язык: Английский

Процитировано

12
PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis DOI Creative Commons
Francisco Cézar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Barbara Lins Silva

и другие.

Journal of Gastrointestinal Cancer, Год журнала: 2025, Номер 56(1)

Опубликована: Янв. 20, 2025

Язык: Английский

Процитировано

1
A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects DOI Creative Commons
David Amilo, Chinedu Izuchukwu, Khadijeh Sadri

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Авг. 9, 2024

Abstract This research presents a novel approach to address the complexities of heterogeneous lung cancer dynamics through development Fractional-Order Model. Focusing on optimization combination therapy, model integrates immunotherapy and targeted therapy with specific aim minimizing side effects. Notably, our incorporates clever fusion Proportional-Integral-Derivative (PID) feedback controls alongside process. Unlike previous studies, essential equations accounting for interaction between regular mutated cells, delineates immune cells enhances cell cytotoxic activity, elucidates influence genetic mutations spread cells. refined offers comprehensive understanding progression, providing valuable tool personalized effective treatment strategies. findings underscore potential optimized strategy in achieving key therapeutic goals, including primary tumor control, metastasis limitation, response enhancement, controlled mutations. The dynamic adaptive nature approach, coupled economic considerations memory effects, positions at forefront advancing precision therapeutics.

Язык: Английский

Процитировано

7
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance DOI Open Access
Liqin Yao,

Qingqing Wang,

Wenxue Ma

и другие.

Cancers, Год журнала: 2023, Номер 15(24), С. 5857 - 5857

Опубликована: Дек. 15, 2023

Cancer immunotherapy has ushered in a transformative era oncology, offering unprecedented promise and opportunities. Despite its remarkable breakthroughs, the field continues to grapple with persistent challenge of treatment resistance. This resistance not only undermines widespread efficacy these pioneering treatments, but also underscores pressing need for further research. Our exploration into intricate realm cancer reveals various mechanisms at play, from primary secondary significant impact genetic epigenetic factors, as well crucial role tumor microenvironment (TME). Furthermore, we stress importance devising innovative strategies counteract this resistance, such employing combination therapies, tailoring immune checkpoints, implementing real-time monitoring. By championing state-of-the-art methods, anticipate paradigm that blends personalized healthcare improved options is firmly committed patient welfare. Through comprehensive multifaceted approach, strive tackle challenges aspiring elevate beacon hope patients around world.

Язык: Английский

Процитировано

13
Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials DOI
Francisco Cézar Aquino de Moraes, Artur de Oliveira Macena Lôbo, Vitor Kendi Tsuchiya Sano

и другие.

Clinical Oncology, Год журнала: 2024, Номер 36(10), С. e408 - e419

Опубликована: Июль 2, 2024

Язык: Английский

Процитировано

5
Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation DOI

Paras Famta,

Saurabh Shah,

Ganesh Vambhurkar

и другие.

Drug Delivery and Translational Research, Год журнала: 2024, Номер 15(2), С. 389 - 406

Опубликована: Июль 15, 2024

Язык: Английский

Процитировано

5
Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis DOI Creative Commons
Lavinia Balan, Anca Maria Cîmpean,

Prashant Sunil Nandarge

и другие.

Biomedicines, Год журнала: 2024, Номер 12(5), С. 1109 - 1109

Опубликована: Май 16, 2024

This systematic review evaluates the clinical outcomes and molecular predictors of response to pembrolizumab in patients with advanced metastatic cervical cancer. We adhered PRISMA guidelines for reviews, conducting a database search PubMed, Scopus, Embase. The eligibility criteria centered on outcomes, including overall survival (OS), progression-free (PFS), immune-related biomarkers post-pembrolizumab therapy. included both prospective retrospective studies that detailed characteristics predictive therapeutic response. Our yielded six involving 846 treated from 2017 2022. meta-analysis these showed pembrolizumab, used as monotherapy or combination chemotherapy, extended OS by weighted median 10.35 months PFS 8.50 months. treatment demonstrated pooled objective rate (ORR) 22.39%, although I

Язык: Английский

Процитировано

4
Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer DOI Creative Commons
Ke Wang,

Chuangjie Zheng,

Xinrong Chen

и другие.

Frontiers in Oncology, Год журнала: 2025, Номер 14

Опубликована: Янв. 28, 2025

Objective To compare the efficacy and safety of programmed cell death 1 inhibitors plus chemotherapy (PD-1 + Chemo) ligand (PD-L1 for treatment extensive-stage small-cell lung cancer (ES-SCLC). Methods We performed a meta-analysis relevant data using R software, considering overall survival (OS), progression-free (PFS), grade ≥ 3 treatment-related adverse events (TRAES). Results PD-1 Chemo (OS: hazard ratio [HR] 0.71; PFS: HR 0.59) PD-L1 0.72; 0.73) significantly prolonged did not increase incidence ≥3 TRAEs compared with chemotherapy. Indirect comparisons showed no significant difference in clinical 0.99, 95% CI: 0.86–1.1; 0.80, 0.61–1.0) or (HR 1.0, 0.93–1.1) between Chemo. Non-cumulative probability ranking plot results that ranked first OS PFS. Patients expression levels < 1%, trend disadvantage 1.3; 1.2), whereas patients advantage 0.85; 0.85). Conclusions PFS ES-SCLC TRAES. The profiles appear to be similar.

Язык: Английский

Процитировано

0